{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:24Z","timestamp":1787014284028,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Emicizumab is the initial subcutaneously administered bispecific antibody approved as a prophylactic treatment for patients with haemophilia A (PwHA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study assessed the economic evaluation of emicizumab treatment for non\u2010inhibitor severe haemophilia A (HA) patients in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model evaluated the cost\u2010effectiveness of emicizumab prophylaxis compared to on\u2010demand therapy (ODT), low\u2010dose prophylaxis (LDP; 1565\u00a0IU\/kg\/year), intermediate\u2010dose prophylaxis (IDP; 3915\u00a0IU\/kg\/year) and high\u2010dose prophylaxis (HDP; 7125\u00a0IU\/kg\/year) for HA patients without factor VIII inhibitors. Inputs from HAVEN\u20101 and HAVEN\u20103 trials included transition probabilities of different bleeding types. Costs and benefits were discounted at a 3.5% annual rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base\u2010case analysis, emicizumab was cost\u2010effective compared to HDP, with an incremental cost\u2010effectiveness ratio (ICER) per quality\u2010adjusted life\u2010years (QALY) of Indian rupees (INR) 27,869. Compared to IDP, ODT and LDP, emicizumab prophylaxis could be considered a cost\u2010effective option if the paying threshold is &gt;1 per capita gross domestic product (GDP) with ICER\/QALY values of INR 264,592, INR 255,876 and INR 305,398, respectively. One\u2010way sensitivity analysis (OWSA) highlighted emicizumab cost as the parameter with the greatest impact on ICERs. Probabilistic sensitivity analysis (PSA) indicated that emicizumab had a 94.7% and 49.4% probability of being cost\u2010effective at willingness\u2010to\u2010pay (WTP) thresholds of three and two\u2010times per capita GDP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Emicizumab prophylaxis is cost\u2010effective compared to HDP and provides value for money compared to ODT, IDP, and LDP for severe non\u2010inhibitor PwHA in India. Its long\u2010term humanistic, clinical and economic benefits outweigh alternative options, making it a valuable choice in resource\u2010constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.14921","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T10:51:40Z","timestamp":1703587900000},"page":"426-436","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost\u2010effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9760-7957","authenticated-orcid":false,"given":"Tulika","family":"Seth","sequence":"first","affiliation":[{"name":"Department of Hematology All India Institute of Medical Sciences (AIIMS)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-7332","authenticated-orcid":false,"given":"M. Joseph","family":"John","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology Christian Medical College and Hospital  Ludhiana Punjab India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantar","family":"Chakrabarti","sequence":"additional","affiliation":[{"name":"Department of Haematology NRS Medical College  Kolkata India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-866X","authenticated-orcid":false,"given":"Chandrakala","family":"Shanmukhaiah","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology Seth GSM and KEM Hospital  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra Prasad","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology King George's Medical University  Lucknow Uttar Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology &amp; Oncology Post Graduate Institute of Child Health  Noida India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuphan Kanti","family":"Dolai","sequence":"additional","affiliation":[{"name":"Department of Hematology NRS Medical College and Hospital  Kolkata India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Federation of Hemophilia.Report on the Annual Global Survey 2021 \u2010 eLearning Platform [Internet]. [cited 2023 Apr 28].Accessed on June17 2023.https:\/\/elearning.wfh.org\/resource\/report\u2010on\u2010the\u2010annual\u2010global\u2010survey\u20102021"},{"key":"e_1_2_9_3_1","unstructured":"Hemophilia Federation India.Annual Report 2017\u20132018. Accessed on June 17 2023.AR 2018.cdr (hemophilia.in)."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09723757.2006.11885944"},{"key":"e_1_2_9_5_1","unstructured":"World Federation of Hemophilia.Severity of hemophilia. Accessed 22 October 2021.https:\/\/www.wfh.org\/en\/page.aspx?pid=643"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13028"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S44694"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_2_9_13_1","unstructured":"Roche India.Media Release. Accessed 5 October 2021.Available at: Emicizumab_press release.pdf (rocheindia.com)."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19406"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100039\u20103401822"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14143"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288\u2010019\u201001147\u20100"},{"key":"e_1_2_9_18_1","unstructured":"Disabled World.(30 November 2017). Average height to weight chart: babies to teenagers. Disabled World. Content last updated July 03 2023. Accessed on June 17 2023.www.disabled\u2010world.com\/calculators\u2010charts\/height\u2010weight\u2010teens.php"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2336.2336"},{"key":"e_1_2_9_20_1","unstructured":"MediFee.Doctor visit charges. Accessed on June17 2023. Doctor Visit Charges in India (medifee.com)"},{"key":"e_1_2_9_21_1","unstructured":"Firstpost.India's per capita expenditure on healthcare among lowest in the world; govt spends as little as Rs 3 per day on each citizen. Content last updated June 21 2018. Accessed on June 17 2023. India's per capita expenditure on healthcare among lowest in the world; govt spends as little as Rs 3 per day on each citizen\u2010India News Firstpost."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2016.11.003"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/2394\u20102010.199329"},{"key":"e_1_2_9_24_1","volume-title":"A Manual. Compiled by Department of Health Research, Ministry of Health and Family Welfare, India","author":"Health Technology Assessment in India","year":"2018"},{"key":"e_1_2_9_25_1","volume-title":"Making Choices in Health: WHO Guide to Cost\u2010effectiveness Analysis","author":"World Health Organization","year":"2003"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.014"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.016"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102516.2003.00783.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.5.667"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14129"},{"issue":"1","key":"e_1_2_9_31_1","first-page":"19","article-title":"Epidemiology & social costs of haemophilia in India","volume":"140","author":"Kar A","year":"2014","journal-title":"Indian J Med Res"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1669614"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201002\u2010683169"},{"key":"e_1_2_9_34_1","unstructured":"CastamanG SantagostinoE HovingaJK et\u00a0al.Surgical experience from the phase III STASEY trial of emicizumab prophylaxis in persons with hemophilia A (PwHA) with FVIII inhibitors: data from the second interim analysis.Poster presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress 12\u201014 2020."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2021.03.004"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010128083"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14642"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561\u2010018\u20100185\u20107"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.33393\/grhta.2021.2234"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T22:07:18Z","timestamp":1714428438000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/hae.14921"],"URL":"https:\/\/doi.org\/10.1111\/hae.14921","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"2023-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}